No abstract

No abstract

Graphical abstract

No abstract

A 6-week, randomized, open-label, active-controlled clinical trial was conducted to evaluate the influence of a low-dose curcumagalactomannosides (CGM) (400 mg once daily) in OA subjects. The treatment was compared with a standard combination of 500 mg glucosamine hydrochloride (GLN) and 415 mg chondroitin sulphate (CHN), supplied as a single oral dose twice a day. Out of 84 subjects randomized, 72 subjects who have completed the study were evaluated for the safety and efficacy of the treatments at baseline and subsequent visits (day 28 and 42), by measuring walking performance, VAS, KPS, and WOMAC scores. CGM exhibited 47.02, 21.43, and 206% improvement in VAS, KPS, and walking performance, respectively, compared to the baseline. Similarly, there was 31.17, 32.93, 36.44, and 35% improvement in the pain, stiffness, physical function, and total WOMAC scores. CGM also caused a substantial reduction in the serum inflammatory marker levels. The results indicate that a short-term supplementation of a low dosage CGM exerted superior beneficial effects than a high-dosage CHN-GLN combination in alleviating the pain and symptoms of OA subjects. Further clinical trials of extended duration in a larger population is required to substantiate the efficacy of CGM in the long-term management of OA.

No abstract

Diabetes is a complex chronic disease that affects not only an individual's physical health, but can also have a profound impact on mental wellbeing. The aim of this study was to assess the prevalence of DRD among subjects with type 2 diabetes (T2DM) using Diabetes Distress Scale-17 (DDS-17) and to see its correlation with glycemic control and treatment modalities. A cross-sectional study of 400 T2DM subjects (200 men and 200 women) aged between 25 to 65 years who visited the tertiary care centre for diabetes in South India between April 2017 and May 2018 were included in this study. Subjects with T1DM, gestational diabetes mellitus (GDM) and psychiatric illness were excluded. The total score of DDS-17 was calculated by taking a sum of the 17 items' results and then dividing the total by 17. Clinical validation of the DDS suggests that the following thresholds of severity should be applied when interpreting the scores: little or no distress < 2.0, moderate distress = 2.0-2.9, and high distress ≥ 3.0. The mean age of men and women was 52.0 ± 8.4 and 51.7 ± 8.1 years, respectively. The mean score in women was 2.79 ± 1.52 as compared to men (1.62 ± 0.83) (p<0.001). The study findings highlighted that women had high levels of distress in managing diabetes as compared to men. Diabetes distress should be considered as a significant health problem and steps should be taken for effective management by lifestyle modifications, coping with their stress and diabetes.

No abstract